Depth of Response and Progression-Free Survival in CLL Patients on Ibrutinib

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [31] Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
    Imai, Hisao
    Mori, Keita
    Wakuda, Kazushige
    Ono, Akira
    Akamatsu, Hiroaki
    Shukuya, Takehito
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Kaira, Kyoichi
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    ANNALS OF THORACIC MEDICINE, 2015, 10 (01) : 61 - 66
  • [32] Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib
    Terashima, Takeshi
    Yamashita, Tatsuya
    Takata, Noboru
    Nakagawa, Hidetoshi
    Toyama, Tadashi
    Arai, Kuniaki
    Kitamura, Kazuya
    Yamashita, Taro
    Sakai, Yoshio
    Mizukoshi, Eishiro
    Honda, Masao
    Kaneko, Shuichi
    HEPATOLOGY RESEARCH, 2016, 46 (07) : 650 - 656
  • [33] Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
    Cohen, Steven J.
    Punt, Cornelis J. A.
    Iannotti, Nicholas
    Saidman, Bruce H.
    Sabbath, Kert D.
    Gabrail, Nashat Y.
    Picus, Joel
    Morse, Michael
    Mitchell, Edith
    Miller, M. Craig
    Doyle, Gerald V.
    Tissing, Henk
    Terstappen, Leon W. M. M.
    Meropol, Neal J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) : 3213 - 3221
  • [34] Imaging progression-free survival: How much does it matter to patients?
    O'Donnell, Jennifer
    Robinson, Andrew George
    Booth, Christopher M.
    Koven, Rachel
    Eisenhauer, Elizabeth A.
    Brundage, Michael Donald
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [35] Potential prognostic factors in progression-free survival for patients with cervical cancer
    Hui-Hui Chen
    Wei-Yu Meng
    Run-Ze Li
    Qing-Yi Wang
    Yu-Wei Wang
    Hu-Dan Pan
    Pei-Yu Yan
    Qi-Biao Wu
    Liang Liu
    Xiao-Jun Yao
    Min Kang
    Elaine Lai-Han Leung
    BMC Cancer, 21
  • [36] T-antigen as a biomarker of progression-free survival in patients with glioblastoma
    Guan, Liao
    Wang, Wenwen
    Ji, Xuefei
    Cheng, Hongwei
    Du, Weidong
    Ye, Lei
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (07): : 1765 - 1774
  • [37] The value of progression-free survival to patients with advanced-stage cancer
    Lesley J. Fallowfield
    Anne Fleissig
    Nature Reviews Clinical Oncology, 2012, 9 : 41 - 47
  • [38] The value of progression-free survival to patients with advanced-stage cancer
    Fallowfield, Lesley J.
    Fleissig, Anne
    NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (01) : 41 - 47
  • [39] Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients
    Hogdall, Estrid
    Fung, Eric T.
    Christensen, Ib Jarle
    Yip, Christine
    Nedergaard, Lotte
    Engelholm, Svend Aage
    Risum, Signe
    Petri, Anette Lykke
    Lundvall, Lene
    Lomas, Lee
    Hogdall, Claus
    PROTEOMICS CLINICAL APPLICATIONS, 2010, 4 (12) : 940 - 952
  • [40] Predicting the probability of progression-free survival in patients with small hepatocellular carcinoma
    Cheng, SJ
    Freeman, RB
    Wong, JB
    LIVER TRANSPLANTATION, 2002, 8 (04) : 323 - 328
12345